Majority agreement was reached for the statement that CCL14 values ≤ 1.30 ng/mL can be informative for certain aspects of AKI management and care processes, including drug dosing, exposure to nephrotoxins and family discussions on patient prognosis. This evidence concerns the gene CCL14 and acute kidney injury.